ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02432235
Recruitment Status : Active, not recruiting
First Posted : May 4, 2015
Last Update Posted : October 17, 2018
Sponsor:
Information provided by (Responsible Party):
ADC Therapeutics S.A.

Brief Summary:

This study evaluates ADCT-301 in patients with relapsed/refractory Non-Hodgkin or Hodgkin lymphoma. Patients will participate in a dose-escalation phase (Part 1) and receive escalating doses of ADCT-301 every 3 weeks.

In Part 2 of the study, patients will receive a recommended dose(s) of ADCT-301 every 3 weeks.


Condition or disease Intervention/treatment Phase
Hodgkin Lymphoma Non-Hodgkin Lymphoma Burkitt's Lymphoma Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Lymphoma, Large B-Cell, Diffuse Lymphoma, Follicular Lymphoma, Mantle-Cell Lymphoma, Marginal Zone Waldenstrom's Macroglobulinaemia Lymphoma,T-cell Cutaneous Lymphoma, T-Cell, Peripheral Drug: ADCT-301 Phase 1

Detailed Description:

This is a Phase I, first in human clinical study with ADCT-301 to evaluate the safety and tolerability and pharmacokinetics of ADCT-301 in patients with relapsed/refractory lymphoma.

ADCT-301 is a human monoclonal antibody attached via a cleavable linker to a pyrrolobenzodiazepine (PBD) warhead which, when internalized by antigen expressing cells, covalently cross links deoxyribonucleic acid (DNA) preventing replication.

The study will be conducted in 2 parts: In part 1 (dose escalation) up to 80 patients will receive an infusion of ADCT-301 on Day 1, every 3 weeks. Dose escalation will continue until the maximum tolerated dose (MTD) is determined.

In Part 2 (expansion) up to 60 patients will be assigned to receive the recommended dose(s) of ADCT-301 as determined by a Dose Escalation Steering Committee.

For each patient, the study will include a screening period (up to 28 days), a treatment period, and a follow-up period to assess disease progression and survival for up to 12 months after the last dose of study drug. The total study duration will be dependent on overall patient tolerability to the study drug and response to treatment. It is anticipated that the entire study (Parts 1 and 2) could last approximately 3 years from first patient treated to last patient completed.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 140 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients With Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Study Start Date : June 2015
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : June 2019


Arm Intervention/treatment
Experimental: ADCT-301

In Part 1 (dose-escalation), patients will receive a 1-hour intravenous infusion of ADCT-301 on Day 1 every 3 weeks (21-day cycle). Dose escalation will be conducted according to a continual reassessment method.

In Part 2 (expansion), patients will be assigned to receive the recommended dose(s) of ADCT-301 as determined by the Dose Escalation Steering Committee (DESC).

Drug: ADCT-301
intravenous infusion
Other Name: Camidanlumab tesirine




Primary Outcome Measures :
  1. Assessment of Dose Limiting Toxicities in Determination of the Maximum Tolerated Dose [ Time Frame: The protocol-defined assessment period is 1 21-day cycle ]
    Dose Limiting toxicities as defined per protocol, as related to ADCT-301


Secondary Outcome Measures :
  1. Overall Response Rate, Duration of Response, Progression Free Survival, and Overall Survival (composite endpoint) [ Time Frame: Disease assessments will occur within 6 days prior to Day 1 of Cycles 3 and 5 and thereafter every third cycle until progression of disease or initiation of a new anticancer therapy for up to 12 months. ]
    Date of disease progression will be defined as the earliest date of radiological disease progression as assessed by the investigator using the 2014 Lugano Classification for response for Hodgkin and Non-Hodgkin Lymphoma or Global Response Score criteria for disease progression

  2. Pharmacokinetics and Pharmacodynamics assessment - Total Antibody Hu-Max-TAC, pyrrolobenzodiazepine (PBD) conjugated HuMax-TAC and free warhead SG3199 [ Time Frame: Blood sample collection on Day 1, 8 and 15 of 21-day cycles 1 and 2. ]
    Noncompartmental analysis of the maximum concentration (Cmax)

  3. Pharmacokinetics and Pharmacodynamics assessment - Total Antibody Hu-Max-TAC, pyrrolobenzodiazepine (PBD) conjugated HuMax-TAC and free warhead SG3199 [ Time Frame: Blood sample collection on Day 1, 8 and 15 of 21-day cycles 1 and 2. ]
    Noncompartmental analysis of the time to maximum concentration (Tmax)

  4. Pharmacokinetics and Pharmacodynamics assessment - Total Antibody Hu-Max-TAC, pyrrolobenzodiazepine (PBD) conjugated HuMax-TAC and free warhead SG3199 [ Time Frame: Blood sample collection on Day 1, 8 and 15 of 21-day cycles 1 and 2. ]
    Noncompartmental analysis of the area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0 last)

  5. Pharmacokinetics and Pharmacodynamics assessment - Total Antibody Hu-Max-TAC, pyrrolobenzodiazepine (PBD) conjugated HuMax-TAC and free warhead SG3199 [ Time Frame: Blood sample collection on Day 1, 8 and 15 of 21-day cycles 1 and 2. ]
    Noncompartmental analysis of the area under the concentration-time curve from time zero to the end of the dosing interval (AUC0-τ)

  6. Pharmacokinetics and Pharmacodynamics assessment - Total Antibody Hu-Max-TAC, pyrrolobenzodiazepine (PBD) conjugated HuMax-TAC and free warhead SG3199 [ Time Frame: Blood sample collection on Day 1, 8 and 15 of 21-day cycles 1 and 2. ]
    Noncompartmental analysis of the area under the concentration-time curve from time zero to infinity (AUC0-∞)

  7. Pharmacokinetics and Pharmacodynamics assessment - Total Antibody Hu-Max-TAC, pyrrolobenzodiazepine (PBD) conjugated HuMax-TAC and free warhead SG3199 [ Time Frame: Blood sample collection on Day 1, 8 and 15 of 21-day cycles 1 and 2. ]
    Noncompartmental analysis of the accumulation index (AI)

  8. Pharmacokinetics and Pharmacodynamics assessment - Total Antibody Hu-Max-TAC, pyrrolobenzodiazepine (PBD) conjugated HuMax-TAC and free warhead SG3199 [ Time Frame: Blood sample collection on Day 1, 8 and 15 of 21-day cycles 1 and 2. ]
    Noncompartmental analysis of the volume of distribution at a steady-state (Vss)

  9. Pharmacokinetics and Pharmacodynamics assessment - Total Antibody Hu-Max-TAC, pyrrolobenzodiazepine (PBD) conjugated HuMax-TAC and free warhead SG3199 [ Time Frame: Blood sample collection on Day 1, 8 and 15 of 21-day cycles 1 and 2. ]
    Noncompartmental analysis of the mean residence time (MRT)

  10. Pharmacokinetics and Pharmacodynamics assessment - Total Antibody Hu-Max-TAC, pyrrolobenzodiazepine (PBD) conjugated HuMax-TAC and free warhead SG3199 [ Time Frame: Blood sample collection on Day 1, 8 and 15 of 21-day cycles 1 and 2. ]
    Noncompartmental analysis of the terminal elimination phase rate constant (λz)

  11. Pharmacokinetics and Pharmacodynamics assessment - Total Antibody Hu-Max-TAC, pyrrolobenzodiazepine (PBD) conjugated HuMax-TAC and free warhead SG3199 [ Time Frame: Blood sample collection on Day 1, 8 and 15 of 21-day cycles 1 and 2. ]
    Noncompartmental analysis of T1/2

  12. Pharmacokinetics and Pharmacodynamics assessment - Total Antibody Hu-Max-TAC, pyrrolobenzodiazepine (PBD) conjugated HuMax-TAC and free warhead SG3199 [ Time Frame: Blood sample collection on Day 1, 8 and 15 of 21-day cycles 1 and 2. ]
    Noncompartmental analysis of CL

  13. Pharmacokinetics and Pharmacodynamics assessment - Total Antibody Hu-Max-TAC, pyrrolobenzodiazepine (PBD) conjugated HuMax-TAC and free warhead SG3199 [ Time Frame: Blood sample collection on Day 1, 8 and 15 of 21-day cycles 1 and 2. ]
    Noncompartmental analysis of Vz

  14. Evaluation of anti-drug antibodies (ADAs) in blood before, during, and after treatment with ADCT 301 [ Time Frame: Blood sample collection on Day 1 of each 21 day cycle ]
    Expressed as either negative or positive titer expressed as a dilution factor



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female age 18 years or older.
  2. Refractory or relapsed lymphoma (per World Health Organization (WHO) Classification system)
  3. Pathologically confirmed relapsed or refractory lymphoma
  4. Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block.
  5. Measurable disease, defined by the 2014 Lugano Classification Criteria
  6. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
  7. Absolute neutrophil count ≥1500/µL.
  8. Platelet count of ≥75000/µL.
  9. Hemoglobin ≥9.0 g/dL without transfusion within the 2 weeks prior to Day 1.
  10. Creatinine ≤1.5mg/dL
  11. Serum alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase ≤2 times the upper limit of normal (ULN); ≤ 5 times ULN if there is liver or bone involvement.
  12. Total serum bilirubin ≤1.5 times ULN
  13. Women of childbearing potential must have a negative serum beta-human chorionic gonadotropin pregnancy test within 7 days prior to Day 1.
  14. Women of childbearing potential must agree to use a highly effective method of contraception. Men with female partners who are of childbearing potential must agree that they or their partners will use a highly effective method of contraception.

Exclusion Criteria:

  1. Patients who have an option for any treatment with proven clinical benefit for their lymphoid malignancy at current state of disease.
  2. Active graft-versus-host disease.
  3. Autologous or allogenic transplant within the 60 days prior to Cycle 1 Day 1.
  4. Evidence of myelodysplasia or myeloid leukemia by morphology, immunostains, flow cytometry, or cytogenetics on a bone marrow aspirate or biopsy.
  5. Known history of positive serum human anti-drug antibody (ADA), or known allergy to any component of ADCT-301
  6. History of symptomatic autoimmune disease
  7. Known seropositive for human immunodeficiency (HIV) virus, hepatitis B surface antigen (HbsAg), or antibody to hepatitis C virus (anti-HCV)
  8. History of Steven's Johnson's syndrome or toxic epidermal necrolysis syndrome.
  9. Pregnant or breastfeeding women.
  10. Significant medical comorbidities, including uncontrolled hypertension (diastolic blood pressure greater than 115 mm Hg), unstable angina, congestive heart failure (greater than New York Heart Association class II), severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia, poorly controlled diabetes, severe chronic pulmonary disease, coronary angioplasty, or myocardial infarction within 6 months prior to screening, or uncontrolled atrial or ventricular cardiac arrhythmias.
  11. Use of any other experimental medication(s) within 14 days prior to start of the study treatment.
  12. Major surgery, radiotherapy, chemotherapy, or other anti-neoplastic therapy (including prednisone ≥ 40 mg/day or equivalent) within 14 days or 5 half-lives (whichever is shorter) prior to Cycle 1, Day 1 treatment.
  13. Failure to recover (to Common Terminology Criteria for Adverse Events [CTCAE Version 4.0] Grade 0 or Grade 1) from acute non-hematologic toxicity (except alopecia or Grade 2 or lower neuropathy), due to previous therapy, prior to Screening.
  14. Congenital long QT syndrome or a corrected QTc interval ≥ 470 ms at screening
  15. Active second primary malignancy other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy
  16. Any other significant medical illness, abnormality, or condition

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02432235


Locations
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
United States, Ohio
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States, 44106
United States, Texas
The University of Texas/MD Anderson Cancer Center
Houston, Texas, United States, 77030-4009
Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States, 78229
United States, Virginia
Virginia Cancer Specialists, PC
Fairfax, Virginia, United States, 22031
United States, Wisconsin
Froedtert Hospital/Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
United Kingdom
Guy's and St. Thomas' Hospital NHS Trust
London, England, United Kingdom, SE1 9RT
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, England, United Kingdom
Churchill Hospital, Oxford University Hospitals NHS Foundation Trust
Oxford, England, United Kingdom, OX3 7LE
The Christie NHS Foundation Trust
Manchester, Greater Manchester, United Kingdom, M20 4BX
Southampton General Hospital, University Hospital Southampton NHS Foundation Trust
Southampton, Hampshire, United Kingdom
Sponsors and Collaborators
ADC Therapeutics S.A.

Responsible Party: ADC Therapeutics S.A.
ClinicalTrials.gov Identifier: NCT02432235     History of Changes
Other Study ID Numbers: ADCT-301-001
First Posted: May 4, 2015    Key Record Dates
Last Update Posted: October 17, 2018
Last Verified: October 2018

Keywords provided by ADC Therapeutics S.A.:
Camidanlumab tesirine

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Hodgkin Disease
Burkitt Lymphoma
Waldenstrom Macroglobulinemia
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Follicular
Lymphoma, T-Cell
Lymphoma, Mantle-Cell
Lymphoma, T-Cell, Peripheral
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia
Leukemia, B-Cell
Epstein-Barr Virus Infections
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Tumor Virus Infections
Lymphoma, B-Cell
Neoplasms, Plasma Cell
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases